---
title: "PQQ (Pyrroloquinoline Quinone): Dosing & Vendor Prices"
description: "PQQ (Pyrroloquinoline Quinone): dosing protocols, mechanism & side effects, 1520 PubMed studies. Compare verified vendor prices."
lang: en
json-ld: |
  [
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.bodyhackguide.co/"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Compounds",
          "item": "https://www.bodyhackguide.co/compare"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "PQQ (Pyrroloquinoline Quinone)"
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "PQQ (Pyrroloquinoline Quinone)",
      "description": "Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited. The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion. PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either. PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ. The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates. The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces \"new mitochondria\" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited. The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue. The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted. BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.",
      "lastReviewed": "2026-05-04T11:35:19.695+00:00",
      "url": "https://www.bodyhackguide.co/compound/pqq",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "PQQ (Pyrroloquinoline Quinone)",
        "alternateName": [
          "PQQ",
          "Pyrroloquinoline quinone",
          "Methoxatin",
          "PQQ disodium salt",
          "Pyrroloquinoline quinone disodium",
          "BioPQQ",
          "MGCPQQ",
          "PureQQ",
          "4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid",
          "PQQH2",
          "PQQ hydroquinone",
          "Reduced PQQ",
          "Coenzyme PQQ",
          "Quinone cofactor",
          "o-Quinone cofactor"
        ],
        "description": "Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited. The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion. PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either. PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ. The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates. The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces \"new mitochondria\" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited. The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue. The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted. BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.",
        "activeIngredient": "PQQ (Pyrroloquinoline Quinone)",
        "mechanismOfAction": "PQQ's mechanism of action in mammalian biology is dominated by three proposed modes: (1) as a redox-active antioxidant/pro-oxidant modulator with exceptional catalytic stability, (2) as an activator of mitochondrial biogenesis via the PGC-1α/NRF1/NRF2/TFAM transcriptional axis, and (3) as a modulator of cell signaling pathways including CREB phosphorylation, NGF expression, and MAPK cascades. Unlike essential vitamins that are prosthetic groups for specific enzymes, PQQ in mammals appears to act more as a signaling molecule and redox modulator than as a defined enzymatic cofactor. This distinction matters because it places PQQ in the same category as many phytochemicals and polyphenols — biologically active dietary molecules with modulatory effects on multiple pathways rather than narrow enzymatic roles. Redox cycling and antioxidant chemistry. PQQ's ortho-quinone can accept electrons from cellular reducing systems (NADH, NADPH, glutathione) to form PQQH2 (the hydroquinone reduced form), which can then donate electrons to reactive oxygen species, oxidized lipids, or other oxidants, regenerating PQQ and completing the redox cycle. This cycling can proceed 20,000-100,000 times per molecule before oxidative degradation, giving PQQ an exceptional catalytic efficiency as an antioxidant. By comparison, vitamin C undergoes approximately 4 redox cycles before destruction in typical cellular environments; tocopherol undergoes a handful before depletion. The high cycling capacity means that very low concentrations of PQQ can have measurable antioxidant effects in cellular and subcellular environments. However, the redox reactivity is a double-edged sword. PQQ is also capable of generating superoxide and reactive oxygen species in some contexts — particularly when cellular reducing equivalents are abundant and the Q-cycling saturates the acceptor systems. This pro-oxidant capacity is thought to underlie PQQ's ability to activate redox-sensitive transcription factors (NRF2, AP-1) at physiologic and low-pharmacologic concentrations. At very high concentrations (micromolar and above), PQQ can induce oxidative stress in cultured cells. The concentration-dependent dual role — antioxidant at low concentrations, pro-oxidant at very high — is a common feature of polyphenols and redox-active molecules, and suggests that supplementation doses should not be excessive. PGC-1α and mitochondrial biogenesis. Chowanadisai 2010 (J Biol Chem) demonstrated that PQQ at physiologic concentrations (nanomolar to low micromolar) activates PGC-1α transcription and protein expression in mouse embryonic fibroblasts and human hepatocytes. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of nuclear-encoded mitochondrial proteins via NRF1 and NRF2 transcription factors, and mitochondrial DNA replication via TFAM. PGC-1α activation also stimulates fatty acid oxidation, oxidative phosphorylation enzyme complexes, and the thermogenic program in adipose tissue. In muscle, PGC-1α expression is induced by exercise and contributes to the mitochondrial adaptations of endurance training. In brain, PGC-1α supports neural metabolism and neuroprotection. The upstream regulation of PGC-1α by PQQ is proposed to involve CREB phosphorylation (cAMP response element binding protein), though the exact molecular bridge from PQQ binding to CREB activation is not fully characterized. Cell culture evidence suggests this pathway is active at PQQ concentrations achievable by oral supplementation, making the mechanism plausible in vivo. The consequence of PGC-1α activation is increased cellular mitochondrial density, improved respiratory capacity per cell, and improved metabolic flexibility. These are attractive outcomes in the context of age-related mitochondrial decline, metabolic disease, and exercise adaptation. Whether PQQ supplementation produces measurable mitochondrial DNA expansion in human tissue (muscle biopsy studies) has not been definitively demonstrated, though indirect markers (exercise capacity, cognitive markers, fatigue) have shown modest positive signals in small trials. CREB and nerve growth factor signaling. PQQ in neuronal cell culture stimulates NGF (nerve growth factor) expression and secretion by glial cells, promoting neuronal growth and survival. NGF is essential for cholinergic neuron maintenance and has been implicated in cognitive preservation. The CREB/NGF axis is one of the proposed mechanisms for PQQ's cognitive effects. In vivo, PQQ supplementation in rodent models has produced modest improvements in memory tasks, with concurrent elevations in NGF and BDNF (brain-derived neurotrophic factor) in hippocampal tissue. The human cognitive trial data (Nakano 2012, Nakano 2009) are consistent with this mechanism but are not definitive. Anti-inflammatory and immunomodulatory effects. PQQ at physiologic concentrations modulates inflammatory cytokine expression. In macrophages, PQQ reduces NF-kB activation, reduces IL-6 and TNF-alpha secretion, and shifts macrophage polarization toward the M2 (anti-inflammatory) phenotype. In vivo, PQQ supplementation in rodent models of inflammation has shown reductions in inflammatory markers and tissue damage. Human data on inflammatory markers with PQQ supplementation are limited — one small trial (Harris 2013 J Nutr Biochem) in 10 healthy subjects showed acute reductions in CRP and IL-6 after single-dose PQQ, but long-term data are lacking. Hypoxia and HIF-1α interactions. PQQ has been shown to modulate hypoxia-inducible factor 1-alpha (HIF-1α) in cell culture, potentially through its effects on oxygen-sensitive prolyl hydroxylases. This mechanism has been proposed as an explanation for PQQ's cardioprotective effects in ischemia-reperfusion models. Clinical relevance in humans is uncertain. Direct binding to quinoprotein-related targets. Given PQQ's native role as a bacterial cofactor, there has been interest in whether mammalian proteins have PQQ-binding sites. LysPQQ (a quinoprotein analog) and a few mammalian proteins have been investigated, but no definitive PQQ-dependent mammalian enzyme has been identified. This contrasts with the clear enzymatic role in bacteria and explains why PQQ has not been classified as a vitamin in mammals despite its biological activity. Exercise and adaptation. PQQ's PGC-1α activation overlaps with the molecular adaptations induced by exercise. In rodent models, PQQ supplementation combined with exercise produces greater mitochondrial adaptations than exercise alone, though the magnitude is modest. Human exercise trials with PQQ have been limited. The theoretical combination of PQQ supplementation with endurance training is mechanistically attractive but clinically unestablished. Integrative summary. PQQ's mechanism involves multiple interacting pathways — redox cycling, PGC-1α activation, CREB/NGF signaling, inflammatory modulation — rather than a single dominant mechanism. The cell biology evidence is substantial and coherent. The translation to human clinical outcomes is less developed. For the supplementation user, the plausible benefits are pleiotropic and subtle: modest mitochondrial support, modest cognitive support, modest anti-inflammatory effect, with no dramatic outcome on any single endpoint but potentially meaningful cumulative benefit over months of use. The pattern resembles other polyphenol and mitochondrial-support supplements — mechanistically interesting, clinically modest, best as an adjunct to foundational nutrition and exercise rather than as a primary intervention.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "Is PQQ an essential vitamin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ has been proposed as a novel B vitamin but has not been formally classified as essential by the IOM, EFSA, or WHO. The 2003 Kasahara Nature paper (PMID 12679798) claimed PQQ was an essential B vitamin, but subsequent analysis determined the specific enzymatic target proposed (AASDH) does not use PQQ as a cofactor in mammals. PQQ-deficient diets in mice produce a reproducible syndrome (growth impairment, reproductive failure, skin fragility; Stites 2000 PMID 10888956), suggesting biological importance, but no mammalian enzyme has been definitively shown to require PQQ as a prosthetic group. PQQ is best described as a biologically active dietary compound with possible nutritional relevance, not a confirmed vitamin."
          }
        },
        {
          "@type": "Question",
          "name": "What is the mechanism of PQQ for mitochondrial biogenesis?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Chowanadisai 2010 J Biol Chem PMID 20022988 demonstrated that PQQ activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) in cell culture at physiologic concentrations. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of mitochondrial proteins via NRF1/NRF2 and mitochondrial DNA replication via TFAM. Activation of this axis produces increased mitochondrial number per cell, improved respiratory capacity, and improved metabolic flexibility. The upstream mechanism involves CREB phosphorylation (cAMP response element binding protein). Whether cell culture effects translate to measurable mitochondrial expansion in human tissue during supplementation has not been definitively demonstrated in biopsy studies, but indirect markers (energy, cognition) have shown some positive signals."
          }
        },
        {
          "@type": "Question",
          "name": "What dose of PQQ is effective?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Human trials have predominantly used 20 mg/day, and this is the dose with best supportive evidence (Nakano 2012 for cognitive effects, Itoh 2016 for sleep and stress). Some users report benefits at 10 mg/day. Doses above 20 mg/day have not been shown in human trials to produce additional benefit, and may increase side effect risk. BodyHackGuide recommends starting at 10 mg/day for 2 weeks, then increasing to 20 mg/day if tolerated and seeking greater effect. The dose-response curve appears to plateau in the 10-20 mg range. Doses above 30-40 mg/day are not evidence-supported."
          }
        },
        {
          "@type": "Question",
          "name": "Can PQQ improve cognitive function?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Nakano 2012 examined 41 middle-aged and elderly Japanese subjects given 20 mg PQQ/day for 12 weeks, showing improvements in memory and attention domains, particularly in subjects with lower baseline cognitive function. Itoh 2016 PMID 26857805 showed modest cognitive and sleep quality improvements at 20 mg/day. These trials are small (under 50 subjects), short-duration (8-12 weeks), and predominantly Japanese. Replication in large Western populations has not occurred. The mechanism involves mitochondrial support in brain tissue, NGF stimulation, and modest antioxidant effects. Expect modest benefits if any; PQQ is not a dramatic cognitive enhancer and not a treatment for established dementia."
          }
        },
        {
          "@type": "Question",
          "name": "Is PQQ safe?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "At supplementation doses (10-20 mg/day), PQQ is well-tolerated in available human trials with minimal adverse effects. Intermediate-duration trials (12 weeks) have shown no clinically significant laboratory or adverse events. Post-marketing surveillance in Japan (where BioPQQ has been sold since 2004) has not revealed safety concerns. Headache is the most common side effect at higher doses (above 30 mg/day). Long-term (1+ year) human safety data are limited but the favorable short-term tolerability suggests no major concerns. Avoid standalone supplementation during pregnancy and lactation due to absence of human safety data. Avoid in advanced kidney disease due to renal excretion dependence."
          }
        },
        {
          "@type": "Question",
          "name": "What is the best PQQ product?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "BioPQQ (disodium salt, Mitsubishi Gas Chemical) is the original patented form used in most human trials and has the most extensive quality and safety data. MGCPQQ is a newer Mitsubishi form with comparable specifications. Reputable brands using BioPQQ or MGCPQQ include Jarrow Formulas, Life Extension, Thorne, Designs for Health, and many others. Third-party testing (USP, NSF, ConsumerLab) has identified PQQ products with substantially less PQQ than labeled, particularly among ultra-low-cost products. PQQ is expensive to produce, and products priced at $10/month or less are unlikely to contain authentic PQQ at labeled concentrations. Always verify certificate of analysis and prefer established brands with third-party certification."
          }
        },
        {
          "@type": "Question",
          "name": "Should PQQ be taken with CoQ10?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, this is the most common and most mechanistically sensible pairing. PQQ activates mitochondrial biogenesis (new mitochondria) while CoQ10 supports electron transport chain function in existing mitochondria. Nakano 2012 combined analysis showed additive cognitive benefit. Typical doses: CoQ10 (ubiquinol preferred in aging adults) 100-200 mg/day plus PQQ 10-20 mg/day. This combination is widely marketed and has the best supportive evidence among PQQ stacking combinations. Budget-conscious users should prioritize CoQ10 (more evidence, often less expensive) and add PQQ as a secondary intervention if budget allows."
          }
        },
        {
          "@type": "Question",
          "name": "Does PQQ help with fatigue?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Some users report subjective energy improvement with PQQ 10-20 mg/day, and this is consistent with the proposed mitochondrial biogenesis mechanism. However, fatigue has many causes — sleep disorders, thyroid disease, anemia, depression, nutritional deficiencies — that should be evaluated and addressed before attributing fatigue to mitochondrial dysfunction and treating with PQQ. Foundational workup (CBC, iron studies, TSH, vitamin D, B12, testosterone in men, sleep evaluation) is essential. If foundational causes are addressed or ruled out, a 12-week trial of PQQ + CoQ10 + B complex + magnesium + omega-3 is reasonable. Do not use PQQ as a substitute for addressing underlying fatigue etiologies."
          }
        },
        {
          "@type": "Question",
          "name": "How quickly does PQQ work?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ plasma steady state is reached within 2-3 days of daily dosing, so direct pharmacologic effects occur rapidly. However, the downstream effects claimed for PQQ supplementation — mitochondrial biogenesis, cognitive enhancement, energy improvement — require adaptation time measured in weeks to months. Nakano 2012 assessed cognitive effects at 12 weeks. Subjective energy changes have been reported by some users within 2-4 weeks, but many users require 6-8 weeks before noticing benefit. BodyHackGuide recommends committing to 8-12 weeks of consistent use before evaluating response. Do not judge efficacy in the first 2 weeks."
          }
        },
        {
          "@type": "Question",
          "name": "Is PQQ worth the cost?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ costs approximately $30-60/month at typical supplementation doses (10-20 mg/day), making it one of the more expensive single-ingredient supplements. The value proposition depends on: (a) individual response (some users perceive meaningful energy or cognitive benefit, others do not); (b) the foundational interventions already in place (sleep, exercise, diet, basic supplements produce greater effects at lower cost for most users); (c) specific goals (for mitochondrial support in aging adults with cognitive concerns, the case is stronger than for young healthy adults). A defensible approach is a 12-week trial with clear benchmarks; continue if subjective benefit; discontinue if not. Many users find that a foundational mitochondrial stack (CoQ10, magnesium, B complex, creatine, omega-3) produces more noticeable effects at similar or lower total cost."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "PQQ (Pyrroloquinoline Quinone)",
      "description": "Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited. The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion. PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either. PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ. The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates. The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces \"new mitochondria\" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited. The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue. The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted. BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.",
      "lastReviewed": "2026-05-04T11:35:19.695+00:00",
      "url": "https://www.bodyhackguide.co/compound/pqq",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "PQQ (Pyrroloquinoline Quinone)",
        "alternateName": [
          "PQQ",
          "Pyrroloquinoline quinone",
          "Methoxatin",
          "PQQ disodium salt",
          "Pyrroloquinoline quinone disodium",
          "BioPQQ",
          "MGCPQQ",
          "PureQQ",
          "4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid",
          "PQQH2",
          "PQQ hydroquinone",
          "Reduced PQQ",
          "Coenzyme PQQ",
          "Quinone cofactor",
          "o-Quinone cofactor"
        ],
        "description": "Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited. The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion. PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either. PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ. The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates. The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces \"new mitochondria\" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited. The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue. The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted. BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.",
        "activeIngredient": "PQQ (Pyrroloquinoline Quinone)",
        "mechanismOfAction": "PQQ's mechanism of action in mammalian biology is dominated by three proposed modes: (1) as a redox-active antioxidant/pro-oxidant modulator with exceptional catalytic stability, (2) as an activator of mitochondrial biogenesis via the PGC-1α/NRF1/NRF2/TFAM transcriptional axis, and (3) as a modulator of cell signaling pathways including CREB phosphorylation, NGF expression, and MAPK cascades. Unlike essential vitamins that are prosthetic groups for specific enzymes, PQQ in mammals appears to act more as a signaling molecule and redox modulator than as a defined enzymatic cofactor. This distinction matters because it places PQQ in the same category as many phytochemicals and polyphenols — biologically active dietary molecules with modulatory effects on multiple pathways rather than narrow enzymatic roles. Redox cycling and antioxidant chemistry. PQQ's ortho-quinone can accept electrons from cellular reducing systems (NADH, NADPH, glutathione) to form PQQH2 (the hydroquinone reduced form), which can then donate electrons to reactive oxygen species, oxidized lipids, or other oxidants, regenerating PQQ and completing the redox cycle. This cycling can proceed 20,000-100,000 times per molecule before oxidative degradation, giving PQQ an exceptional catalytic efficiency as an antioxidant. By comparison, vitamin C undergoes approximately 4 redox cycles before destruction in typical cellular environments; tocopherol undergoes a handful before depletion. The high cycling capacity means that very low concentrations of PQQ can have measurable antioxidant effects in cellular and subcellular environments. However, the redox reactivity is a double-edged sword. PQQ is also capable of generating superoxide and reactive oxygen species in some contexts — particularly when cellular reducing equivalents are abundant and the Q-cycling saturates the acceptor systems. This pro-oxidant capacity is thought to underlie PQQ's ability to activate redox-sensitive transcription factors (NRF2, AP-1) at physiologic and low-pharmacologic concentrations. At very high concentrations (micromolar and above), PQQ can induce oxidative stress in cultured cells. The concentration-dependent dual role — antioxidant at low concentrations, pro-oxidant at very high — is a common feature of polyphenols and redox-active molecules, and suggests that supplementation doses should not be excessive. PGC-1α and mitochondrial biogenesis. Chowanadisai 2010 (J Biol Chem) demonstrated that PQQ at physiologic concentrations (nanomolar to low micromolar) activates PGC-1α transcription and protein expression in mouse embryonic fibroblasts and human hepatocytes. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of nuclear-encoded mitochondrial proteins via NRF1 and NRF2 transcription factors, and mitochondrial DNA replication via TFAM. PGC-1α activation also stimulates fatty acid oxidation, oxidative phosphorylation enzyme complexes, and the thermogenic program in adipose tissue. In muscle, PGC-1α expression is induced by exercise and contributes to the mitochondrial adaptations of endurance training. In brain, PGC-1α supports neural metabolism and neuroprotection. The upstream regulation of PGC-1α by PQQ is proposed to involve CREB phosphorylation (cAMP response element binding protein), though the exact molecular bridge from PQQ binding to CREB activation is not fully characterized. Cell culture evidence suggests this pathway is active at PQQ concentrations achievable by oral supplementation, making the mechanism plausible in vivo. The consequence of PGC-1α activation is increased cellular mitochondrial density, improved respiratory capacity per cell, and improved metabolic flexibility. These are attractive outcomes in the context of age-related mitochondrial decline, metabolic disease, and exercise adaptation. Whether PQQ supplementation produces measurable mitochondrial DNA expansion in human tissue (muscle biopsy studies) has not been definitively demonstrated, though indirect markers (exercise capacity, cognitive markers, fatigue) have shown modest positive signals in small trials. CREB and nerve growth factor signaling. PQQ in neuronal cell culture stimulates NGF (nerve growth factor) expression and secretion by glial cells, promoting neuronal growth and survival. NGF is essential for cholinergic neuron maintenance and has been implicated in cognitive preservation. The CREB/NGF axis is one of the proposed mechanisms for PQQ's cognitive effects. In vivo, PQQ supplementation in rodent models has produced modest improvements in memory tasks, with concurrent elevations in NGF and BDNF (brain-derived neurotrophic factor) in hippocampal tissue. The human cognitive trial data (Nakano 2012, Nakano 2009) are consistent with this mechanism but are not definitive. Anti-inflammatory and immunomodulatory effects. PQQ at physiologic concentrations modulates inflammatory cytokine expression. In macrophages, PQQ reduces NF-kB activation, reduces IL-6 and TNF-alpha secretion, and shifts macrophage polarization toward the M2 (anti-inflammatory) phenotype. In vivo, PQQ supplementation in rodent models of inflammation has shown reductions in inflammatory markers and tissue damage. Human data on inflammatory markers with PQQ supplementation are limited — one small trial (Harris 2013 J Nutr Biochem) in 10 healthy subjects showed acute reductions in CRP and IL-6 after single-dose PQQ, but long-term data are lacking. Hypoxia and HIF-1α interactions. PQQ has been shown to modulate hypoxia-inducible factor 1-alpha (HIF-1α) in cell culture, potentially through its effects on oxygen-sensitive prolyl hydroxylases. This mechanism has been proposed as an explanation for PQQ's cardioprotective effects in ischemia-reperfusion models. Clinical relevance in humans is uncertain. Direct binding to quinoprotein-related targets. Given PQQ's native role as a bacterial cofactor, there has been interest in whether mammalian proteins have PQQ-binding sites. LysPQQ (a quinoprotein analog) and a few mammalian proteins have been investigated, but no definitive PQQ-dependent mammalian enzyme has been identified. This contrasts with the clear enzymatic role in bacteria and explains why PQQ has not been classified as a vitamin in mammals despite its biological activity. Exercise and adaptation. PQQ's PGC-1α activation overlaps with the molecular adaptations induced by exercise. In rodent models, PQQ supplementation combined with exercise produces greater mitochondrial adaptations than exercise alone, though the magnitude is modest. Human exercise trials with PQQ have been limited. The theoretical combination of PQQ supplementation with endurance training is mechanistically attractive but clinically unestablished. Integrative summary. PQQ's mechanism involves multiple interacting pathways — redox cycling, PGC-1α activation, CREB/NGF signaling, inflammatory modulation — rather than a single dominant mechanism. The cell biology evidence is substantial and coherent. The translation to human clinical outcomes is less developed. For the supplementation user, the plausible benefits are pleiotropic and subtle: modest mitochondrial support, modest cognitive support, modest anti-inflammatory effect, with no dramatic outcome on any single endpoint but potentially meaningful cumulative benefit over months of use. The pattern resembles other polyphenol and mitochondrial-support supplements — mechanistically interesting, clinically modest, best as an adjunct to foundational nutrition and exercise rather than as a primary intervention.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "Is PQQ an essential vitamin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ has been proposed as a novel B vitamin but has not been formally classified as essential by the IOM, EFSA, or WHO. The 2003 Kasahara Nature paper (PMID 12679798) claimed PQQ was an essential B vitamin, but subsequent analysis determined the specific enzymatic target proposed (AASDH) does not use PQQ as a cofactor in mammals. PQQ-deficient diets in mice produce a reproducible syndrome (growth impairment, reproductive failure, skin fragility; Stites 2000 PMID 10888956), suggesting biological importance, but no mammalian enzyme has been definitively shown to require PQQ as a prosthetic group. PQQ is best described as a biologically active dietary compound with possible nutritional relevance, not a confirmed vitamin."
          }
        },
        {
          "@type": "Question",
          "name": "What is the mechanism of PQQ for mitochondrial biogenesis?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Chowanadisai 2010 J Biol Chem PMID 20022988 demonstrated that PQQ activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) in cell culture at physiologic concentrations. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of mitochondrial proteins via NRF1/NRF2 and mitochondrial DNA replication via TFAM. Activation of this axis produces increased mitochondrial number per cell, improved respiratory capacity, and improved metabolic flexibility. The upstream mechanism involves CREB phosphorylation (cAMP response element binding protein). Whether cell culture effects translate to measurable mitochondrial expansion in human tissue during supplementation has not been definitively demonstrated in biopsy studies, but indirect markers (energy, cognition) have shown some positive signals."
          }
        },
        {
          "@type": "Question",
          "name": "What dose of PQQ is effective?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Human trials have predominantly used 20 mg/day, and this is the dose with best supportive evidence (Nakano 2012 for cognitive effects, Itoh 2016 for sleep and stress). Some users report benefits at 10 mg/day. Doses above 20 mg/day have not been shown in human trials to produce additional benefit, and may increase side effect risk. BodyHackGuide recommends starting at 10 mg/day for 2 weeks, then increasing to 20 mg/day if tolerated and seeking greater effect. The dose-response curve appears to plateau in the 10-20 mg range. Doses above 30-40 mg/day are not evidence-supported."
          }
        },
        {
          "@type": "Question",
          "name": "Can PQQ improve cognitive function?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Nakano 2012 examined 41 middle-aged and elderly Japanese subjects given 20 mg PQQ/day for 12 weeks, showing improvements in memory and attention domains, particularly in subjects with lower baseline cognitive function. Itoh 2016 PMID 26857805 showed modest cognitive and sleep quality improvements at 20 mg/day. These trials are small (under 50 subjects), short-duration (8-12 weeks), and predominantly Japanese. Replication in large Western populations has not occurred. The mechanism involves mitochondrial support in brain tissue, NGF stimulation, and modest antioxidant effects. Expect modest benefits if any; PQQ is not a dramatic cognitive enhancer and not a treatment for established dementia."
          }
        },
        {
          "@type": "Question",
          "name": "Is PQQ safe?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "At supplementation doses (10-20 mg/day), PQQ is well-tolerated in available human trials with minimal adverse effects. Intermediate-duration trials (12 weeks) have shown no clinically significant laboratory or adverse events. Post-marketing surveillance in Japan (where BioPQQ has been sold since 2004) has not revealed safety concerns. Headache is the most common side effect at higher doses (above 30 mg/day). Long-term (1+ year) human safety data are limited but the favorable short-term tolerability suggests no major concerns. Avoid standalone supplementation during pregnancy and lactation due to absence of human safety data. Avoid in advanced kidney disease due to renal excretion dependence."
          }
        },
        {
          "@type": "Question",
          "name": "What is the best PQQ product?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "BioPQQ (disodium salt, Mitsubishi Gas Chemical) is the original patented form used in most human trials and has the most extensive quality and safety data. MGCPQQ is a newer Mitsubishi form with comparable specifications. Reputable brands using BioPQQ or MGCPQQ include Jarrow Formulas, Life Extension, Thorne, Designs for Health, and many others. Third-party testing (USP, NSF, ConsumerLab) has identified PQQ products with substantially less PQQ than labeled, particularly among ultra-low-cost products. PQQ is expensive to produce, and products priced at $10/month or less are unlikely to contain authentic PQQ at labeled concentrations. Always verify certificate of analysis and prefer established brands with third-party certification."
          }
        },
        {
          "@type": "Question",
          "name": "Should PQQ be taken with CoQ10?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, this is the most common and most mechanistically sensible pairing. PQQ activates mitochondrial biogenesis (new mitochondria) while CoQ10 supports electron transport chain function in existing mitochondria. Nakano 2012 combined analysis showed additive cognitive benefit. Typical doses: CoQ10 (ubiquinol preferred in aging adults) 100-200 mg/day plus PQQ 10-20 mg/day. This combination is widely marketed and has the best supportive evidence among PQQ stacking combinations. Budget-conscious users should prioritize CoQ10 (more evidence, often less expensive) and add PQQ as a secondary intervention if budget allows."
          }
        },
        {
          "@type": "Question",
          "name": "Does PQQ help with fatigue?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Some users report subjective energy improvement with PQQ 10-20 mg/day, and this is consistent with the proposed mitochondrial biogenesis mechanism. However, fatigue has many causes — sleep disorders, thyroid disease, anemia, depression, nutritional deficiencies — that should be evaluated and addressed before attributing fatigue to mitochondrial dysfunction and treating with PQQ. Foundational workup (CBC, iron studies, TSH, vitamin D, B12, testosterone in men, sleep evaluation) is essential. If foundational causes are addressed or ruled out, a 12-week trial of PQQ + CoQ10 + B complex + magnesium + omega-3 is reasonable. Do not use PQQ as a substitute for addressing underlying fatigue etiologies."
          }
        },
        {
          "@type": "Question",
          "name": "How quickly does PQQ work?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ plasma steady state is reached within 2-3 days of daily dosing, so direct pharmacologic effects occur rapidly. However, the downstream effects claimed for PQQ supplementation — mitochondrial biogenesis, cognitive enhancement, energy improvement — require adaptation time measured in weeks to months. Nakano 2012 assessed cognitive effects at 12 weeks. Subjective energy changes have been reported by some users within 2-4 weeks, but many users require 6-8 weeks before noticing benefit. BodyHackGuide recommends committing to 8-12 weeks of consistent use before evaluating response. Do not judge efficacy in the first 2 weeks."
          }
        },
        {
          "@type": "Question",
          "name": "Is PQQ worth the cost?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "PQQ costs approximately $30-60/month at typical supplementation doses (10-20 mg/day), making it one of the more expensive single-ingredient supplements. The value proposition depends on: (a) individual response (some users perceive meaningful energy or cognitive benefit, others do not); (b) the foundational interventions already in place (sleep, exercise, diet, basic supplements produce greater effects at lower cost for most users); (c) specific goals (for mitochondrial support in aging adults with cognitive concerns, the case is stronger than for young healthy adults). A defensible approach is a 12-week trial with clear benchmarks; continue if subjective benefit; discontinue if not. Many users find that a foundational mitochondrial stack (CoQ10, magnesium, B complex, creatine, omega-3) produces more noticeable effects at similar or lower total cost."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    }
  ]
---

[Skip to content](#main-content)

## Research Use Only

This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy).

I'm 21+ — Enter SiteLeave site

  

[![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/)

[Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools)

Learn

Community

Search ⌘K

[Sign In](/auth?returnTo=%2Fcompound%2Fpqq)

100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 

1.  [Home](/)
2.  [Compounds](/compare)
3.  PQQ (Pyrroloquinoline Quinone) 

[Where to buy PQQ (Pyrroloquinoline Quinone)](/buy/pqq) [PQQ (Pyrroloquinoline Quinone) coupon codes](/coupons/pqq) [PQQ (Pyrroloquinoline Quinone) protocol](/protocol/pqq) [Alternatives to PQQ (Pyrroloquinoline Quinone)](/alternatives-to/pqq) [PQQ (Pyrroloquinoline Quinone) side effects](/side-effects/pqq)

1.  [Home](/)

3.  [Compounds](/compare)

5.  PQQ (Pyrroloquinoline Quinone) 

# PQQ (Pyrroloquinoline Quinone)

Cofactor Preclinical 

Download  PDF

Also known as: PQQ, Pyrroloquinoline quinone, Methoxatin, PQQ disodium salt, Pyrroloquinoline quinone disodium, BioPQQ, MGCPQQ, PureQQ, 4,5-dihydro-4,5-dioxo-1H-pyrrolo\[2,3-f\]quinoline-2,7,9-tricarboxylic acid, PQQH2, PQQ hydroquinone, Reduced PQQ, Coenzyme PQQ, Quinone cofactor, o-Quinone cofactor 

Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates.

[1520 PubMed Studies](https://pubmed.ncbi.nlm.nih.gov/?term=PQQ%20OR%20%22pyrroloquinoline%20quinone%22%20OR%20methoxatin%20OR%20%22PQQ%20mitochondrial%22%20OR%20%22PQQ%20cognitive%22%20OR%20%22PQQ%20energy%20metabolism%22%20OR%20%22PQQ%20supplementation%22%20OR%20BioPQQ)

Last reviewed: May 4, 2026 

[

1,520

PubMed Studies



](https://pubmed.ncbi.nlm.nih.gov/?term=PQQ%20OR%20%22pyrroloquinoline%20quinone%22%20OR%20methoxatin%20OR%20%22PQQ%20mitochondrial%22%20OR%20%22PQQ%20cognitive%22%20OR%20%22PQQ%20energy%20metabolism%22%20OR%20%22PQQ%20supplementation%22%20OR%20BioPQQ)[

Cofactor

Category



](/wiki#cat-cofactor)

Preclinical

Research Stage

OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated

## Overview

### At A Glance

Mechanism 

PQQ's mechanism of action in mammalian biology is dominated by three proposed modes: (1) as a redox-active antioxidant/pro-oxidant modulator with exceptional catalytic stability, (2) as an activator of mitochondrial biogenesis via the PGC-1α/NRF1/NRF2/TFAM transcriptional axis, a… 

### Overview

Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited.

The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion.

PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either.

PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ.

The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates.

The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces "new mitochondria" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited.

The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue.

The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted.

BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with [CoQ10](/compound/coq10), [alpha-lipoic acid](/compound/alpha-lipoic-acid), creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.

## Chemical Information

IUPAC Name

Not yet available 

CAS Number

Not yet available 

Molecular Formula

Not yet available 

Molecular Mass

Not yet available 

Chemical data is being compiled for this compound.

## Dosing & Protocols

### Unlock Dosing Protocols

Free account gets you:

-   View beginner, intermediate & advanced protocols 
-   See weight-based dosing calculations 
-   Access cycle length & frequency data 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Research

### Unlock Research Data

Free account gets you:

-   Browse PubMed study summaries 
-   See clinical trial phases & results 
-   Access mechanism of action details 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Interactions

### Contraindications

Absolute contraindications:

-   Known hypersensitivity to PQQ or PQQ-containing products.

Relative contraindications (caution or specialist guidance):

-   Pregnancy: No adequate human data. Standalone supplementation not recommended.
-   Lactation: No adequate human data. Standalone supplementation not recommended.
-   Children: Not recommended outside research contexts.
-   Advanced kidney disease (CKD stage 4-5, dialysis): Accumulation risk due to renal excretion dependence. Avoid or use only under specialist guidance.
-   Active cancer treatment: No data on PQQ in oncology settings. Consult oncology team.
-   Active neurodegenerative disease: PQQ is not a therapy. Standard medical management is primary.
-   Anticoagulation with warfarin: Theoretical concern (quinone structure). Monitor INR if combining.
-   Autoimmune disease: PQQ's immunomodulatory effects are not well studied. Caution.
-   Specific mitochondrial disorders (primary mitochondrial disease): Specialist evaluation required before supplementation.

Drug interactions (theoretical/speculative):

-   Proteasome inhibitors, other quinone-containing drugs: no established interactions; consider total quinone exposure.
-   Metformin, GLP-1 agonists: theoretically complementary mitochondrial effects; no interaction concerns.
-   Statins: theoretically complementary (statins may reduce CoQ10; PQQ supports mitochondrial biogenesis). No interaction.

Populations where supplementation is of unclear value:

-   Young healthy adults without specific fatigue or cognitive concerns.
-   Individuals with established medical conditions who have not first addressed foundational management.
-   Users with limited supplementation budget for whom lower-cost interventions would be higher yield (foundational vitamins, minerals, fish oil, creatine).

Situations warranting discontinuation:

-   Persistent headache not relieved by dose reduction.
-   Sleep disturbance not relieved by timing change.
-   Skin rash or hypersensitivity.
-   Gastrointestinal intolerance.
-   No subjective benefit after 12-week trial.

Quality concerns:

-   Avoid PQQ products without third-party testing or certificate of analysis.
-   Avoid ultra-inexpensive PQQ (likely substandard or mislabeled).
-   Verify BioPQQ or MGCPQQ designation for assurance of authentic content.

Long-term considerations:

-   Long-term (over 1 year) safety data in humans are limited. Favorable short-term tolerability suggests no major concerns, but users should be aware of this evidence gap.
-   Annual reassessment of whether continued supplementation is subjectively beneficial is reasonable.

Special considerations:

-   Users on multiple redox-active supplements (vitamin E, CoQ10, astaxanthin, R-lipoic acid, etc.) may have complex redox interactions. Stack with integrative health professional guidance if pursuing extensive antioxidant protocols.
-   Athletes should be aware that while PQQ is generally permitted by anti-doping regulations, product quality variations mean some products may contain unlisted substances. Use WADA-compliant products if competing.

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

[Sign in for alerts ](/auth)

No listings found for PQQ (Pyrroloquinoline Quinone).

Get PQQ (Pyrroloquinoline Quinone) Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

[Sign in to set alerts](/auth)

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with PQQ (Pyrroloquinoline Quinone).

[Sign in](/auth)

[

View Full Dosage Guide →

Protocols, calculator & safety for PQQ (Pyrroloquinoline Quinone)



](/guides/dosage/pqq)

### Research Score

55 

1520 PubMed studies

### Quality Indicators

Data Completeness

63% 

Description 

Mechanism of Action 

Chemical Data 

Dosing Protocols 

Safety Profile 

PubMed Studies 

Interactions 

Vendor Listings 

Research Credibility

1520 PubMed studies 

Well-researched compound

### Quick Facts

Trial Phase

Preclinical

[Full Dosage Guide](/guides/dosage/pqq)[Calculate Your Dose](/tools/reconstitution)

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

## Frequently Asked Questions

Is PQQ an essential vitamin?

PQQ has been proposed as a novel B vitamin but has not been formally classified as essential by the IOM, EFSA, or WHO. The 2003 Kasahara Nature paper (PMID 12679798) claimed PQQ was an essential B vitamin, but subsequent analysis determined the specific enzymatic target proposed (AASDH) does not use PQQ as a cofactor in mammals. PQQ-deficient diets in mice produce a reproducible syndrome (growth impairment, reproductive failure, skin fragility; Stites 2000 PMID 10888956), suggesting biological importance, but no mammalian enzyme has been definitively shown to require PQQ as a prosthetic group. PQQ is best described as a biologically active dietary compound with possible nutritional relevance, not a confirmed vitamin.

What is the mechanism of PQQ for mitochondrial biogenesis?

Chowanadisai 2010 J Biol Chem PMID 20022988 demonstrated that PQQ activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) in cell culture at physiologic concentrations. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of mitochondrial proteins via NRF1/NRF2 and mitochondrial DNA replication via TFAM. Activation of this axis produces increased mitochondrial number per cell, improved respiratory capacity, and improved metabolic flexibility. The upstream mechanism involves CREB phosphorylation (cAMP response element binding protein). Whether cell culture effects translate to measurable mitochondrial expansion in human tissue during supplementation has not been definitively demonstrated in biopsy studies, but indirect markers (energy, cognition) have shown some positive signals.

What dose of PQQ is effective?

Human trials have predominantly used 20 mg/day, and this is the dose with best supportive evidence (Nakano 2012 for cognitive effects, Itoh 2016 for sleep and stress). Some users report benefits at 10 mg/day. Doses above 20 mg/day have not been shown in human trials to produce additional benefit, and may increase side effect risk. BodyHackGuide recommends starting at 10 mg/day for 2 weeks, then increasing to 20 mg/day if tolerated and seeking greater effect. The dose-response curve appears to plateau in the 10-20 mg range. Doses above 30-40 mg/day are not evidence-supported.

Can PQQ improve cognitive function?

Nakano 2012 examined 41 middle-aged and elderly Japanese subjects given 20 mg PQQ/day for 12 weeks, showing improvements in memory and attention domains, particularly in subjects with lower baseline cognitive function. Itoh 2016 PMID 26857805 showed modest cognitive and sleep quality improvements at 20 mg/day. These trials are small (under 50 subjects), short-duration (8-12 weeks), and predominantly Japanese. Replication in large Western populations has not occurred. The mechanism involves mitochondrial support in brain tissue, NGF stimulation, and modest antioxidant effects. Expect modest benefits if any; PQQ is not a dramatic cognitive enhancer and not a treatment for established dementia.

Is PQQ safe?

At supplementation doses (10-20 mg/day), PQQ is well-tolerated in available human trials with minimal adverse effects. Intermediate-duration trials (12 weeks) have shown no clinically significant laboratory or adverse events. Post-marketing surveillance in Japan (where BioPQQ has been sold since 2004) has not revealed safety concerns. Headache is the most common side effect at higher doses (above 30 mg/day). Long-term (1+ year) human safety data are limited but the favorable short-term tolerability suggests no major concerns. Avoid standalone supplementation during pregnancy and lactation due to absence of human safety data. Avoid in advanced kidney disease due to renal excretion dependence.

What is the best PQQ product?

BioPQQ (disodium salt, Mitsubishi Gas Chemical) is the original patented form used in most human trials and has the most extensive quality and safety data. MGCPQQ is a newer Mitsubishi form with comparable specifications. Reputable brands using BioPQQ or MGCPQQ include Jarrow Formulas, Life Extension, Thorne, Designs for Health, and many others. Third-party testing (USP, NSF, ConsumerLab) has identified PQQ products with substantially less PQQ than labeled, particularly among ultra-low-cost products. PQQ is expensive to produce, and products priced at $10/month or less are unlikely to contain authentic PQQ at labeled concentrations. Always verify certificate of analysis and prefer established brands with third-party certification.

Should PQQ be taken with CoQ10?

Yes, this is the most common and most mechanistically sensible pairing. PQQ activates mitochondrial biogenesis (new mitochondria) while CoQ10 supports electron transport chain function in existing mitochondria. Nakano 2012 combined analysis showed additive cognitive benefit. Typical doses: CoQ10 (ubiquinol preferred in aging adults) 100-200 mg/day plus PQQ 10-20 mg/day. This combination is widely marketed and has the best supportive evidence among PQQ stacking combinations. Budget-conscious users should prioritize CoQ10 (more evidence, often less expensive) and add PQQ as a secondary intervention if budget allows.

Does PQQ help with fatigue?

Some users report subjective energy improvement with PQQ 10-20 mg/day, and this is consistent with the proposed mitochondrial biogenesis mechanism. However, fatigue has many causes — sleep disorders, thyroid disease, anemia, depression, nutritional deficiencies — that should be evaluated and addressed before attributing fatigue to mitochondrial dysfunction and treating with PQQ. Foundational workup (CBC, iron studies, TSH, vitamin D, B12, testosterone in men, sleep evaluation) is essential. If foundational causes are addressed or ruled out, a 12-week trial of PQQ + CoQ10 + B complex + magnesium + omega-3 is reasonable. Do not use PQQ as a substitute for addressing underlying fatigue etiologies.

How quickly does PQQ work?

PQQ plasma steady state is reached within 2-3 days of daily dosing, so direct pharmacologic effects occur rapidly. However, the downstream effects claimed for PQQ supplementation — mitochondrial biogenesis, cognitive enhancement, energy improvement — require adaptation time measured in weeks to months. Nakano 2012 assessed cognitive effects at 12 weeks. Subjective energy changes have been reported by some users within 2-4 weeks, but many users require 6-8 weeks before noticing benefit. BodyHackGuide recommends committing to 8-12 weeks of consistent use before evaluating response. Do not judge efficacy in the first 2 weeks.

Is PQQ worth the cost?

PQQ costs approximately $30-60/month at typical supplementation doses (10-20 mg/day), making it one of the more expensive single-ingredient supplements. The value proposition depends on: (a) individual response (some users perceive meaningful energy or cognitive benefit, others do not); (b) the foundational interventions already in place (sleep, exercise, diet, basic supplements produce greater effects at lower cost for most users); (c) specific goals (for mitochondrial support in aging adults with cognitive concerns, the case is stronger than for young healthy adults). A defensible approach is a 12-week trial with clear benchmarks; continue if subjective benefit; discontinue if not. Many users find that a foundational mitochondrial stack (CoQ10, magnesium, B complex, creatine, omega-3) produces more noticeable effects at similar or lower total cost.

## Research Tools

[

### Peptide Calculator

Reconstitution & syringe units



](/tools/reconstitution)[

### Reconstitution Guide

How to mix, step by step



](/guides/how-to-reconstitute-peptides)[

### Nasal Spray Calc

mL per actuation



](/tools/intranasal)[

### Half-Life Visualizer

Decay curves



](/tools/halflife)

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

[Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-pqq)

### Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH  for first-order discount.

[Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb)

![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)

### BodyHackGuide

Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews.

[support@bodyhackguide.co](mailto:support@bodyhackguide.co)

[](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide)

Explore

#### Explore

-   [Compare prices](/compare)
-   [Research suppliers](/vendors)
-   [Deals](/deals)
-   [Coupons](/coupons)
-   [Nootropics](/nootropics)
-   [Brain health](/brain-health)
-   [Blog](/blog)
-   [Guides](/guides)

Tools

#### Tools

-   [Reconstitution](/tools/reconstitution)
-   [Dosage calculator](/tools/dosage)
-   [Half-life visualizer](/tools/halflife)
-   [COA lookup](/tools/coa)
-   [Cost calculator](/tools/cost-calculator)
-   [Stack builder](/stack-builder)
-   [All tools →](/tools)

Trust & vendors

#### Trust & vendors

-   [Vendor directory](/vendors)
-   [Trust scorecard](/vendors/scorecard)
-   [Get BHG verified](/vendors/get-vetted)
-   [Scoring methodology](/vendors/methodology)
-   [Peptide cheatsheet](/guides/peptide-cheat-sheet-download)

Company

#### Company

-   [About](/about)
-   [Affiliate disclosure](/affiliate-disclosure)
-   [Editorial standards](/editorial-standards)
-   [Creators](/creators)
-   [Coaches](/coaches)
-   [Privacy](/privacy)
-   [Terms](/terms)
-   [Full site directory →](/site-directory)

**Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy)

hi 👋